Recent studies are showing how tumors sidestep targeted cancer drugs by activating other growth-promoting molecules. The findings may help doctors develop new drug combinations that squelch the resistance, said Pasi Janne, senior author of the study and a medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School in Boston.
“Until now we didn’t know what caused acquired resistance to Erbitux,” Janne said in a telephone interview. “Our hope is that this will very rapidly translate into clinical trials” of new drug combinations. The study, done in collaboration with researchers at Kinki University School of Medicine in Osaka, Japan and other universities, is published today in Science Translational Medicine.